2019 CYIR Finalized

47 TOBACCO DEPENDENCE Enid R. Neptune, MD Johns Hopkins School of Medicine Division of Pulmonary and Critical Care Medicine, Institute of Genetic Medicine Baltimore, MD TUESDAY, MAY 21 TOBACCO DEPENDENCE TREATMENT FOR TOBACCO DEPENDENCE Anthenelli R, Benowitz NL, West R, St. Aubin L, McRae T, Lawrence D, Ascher J, Russ C, Krishen A, Evins AE. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomized, placebo-controlled clinical trial. Lancet 2016. 387:2507. Summary The EAGLES trial was a multi-center, double-blind, ran- domized placebo-controlled trial that examined the neu- ropsychiatric consequences of varenicline, bupropion, nicotine patch or placebo in two large cohorts of active smokers (N=8144) over 12 weeks with a further 12-week no treatment follow-up. The study involved 140 centers in 16 countries conducted between 2011-2015. One cohort (N=4074) had a history of psychiatric disorders; the other (N=3984) had no such history. The primary outcome was the incidence of a composite index of moderate and severe neuropsychiatric adverse events with an efficacy endpoint of biochemically-confirmed abstinence during weeks 9-12. In the non-psychiatric cohort, there were no differences in the incidence of neuropsychiatric events across the four treatment groups ranging from 1.3% among varenicline users to 2.5% among users of nicotine patch. The risk- difference of varenicline to placebo was -1.28 (5% CI=-2.40 – 0.15). In the psychiatric cohort, there were no differences among the treatment groups ranging from 4.9% in the placebo group to 6.7% in the bupropion group (6.5% in the varenicline group). The risk difference of varenicline to placebo was insignificant as were the comparison to pla- cebo in the other treatment groups. Persons on varenicline, irrespective of psychiatric history, exhibited the highest abstinence rate compared with other groups. Comments 1. Persons with mental illness have extremely high prevalence of tobacco dependence, ranging from 40-60% depending on the underlying diagnosis. 2. This study provided the most persuasive data that there was no heightened risk of psychiatric decompensation with the use of varenicline, even in persons with mental illness and led to the lifting of the black box warning in December of 2016, a decision that generated some controversy. 3. The study was powered to detect a 4% or greater moderate or severe event incidence in each of the treatment groups, a threshold that was much higher than what has been observed for most drugs making the study underpowered especially using a novel composite endpoint. 4. Unresolved issues are whether the time frame for varenicline use should be flexible depending on the needs of the motivated smoker. 5. The study excluded persons with substance use disorders despite the fact that appreciable crossover effects exist among persons with tobacco dependence and other substance use disorders. Hajek P, Phillips-Waller A, Przulj D, Pesola F, Smith KM, Bisal N, Li J, Parrott S, Sasieni P, Dawkins L, Ross L, Goniewicz M, Wu Q, McRobbie HJ. A Randomized Trial of E-Cigarettes versus Nicotine Replacement Therapy. NEJM 2019 380(7): 629. Summary Among the newer modified risk tobacco products, electron- ic cigarettes have generated the most interest and estab- lished a strong market imprint worldwide. Despite multiple claims, their utility as smoking cessation tools is unresolved. This pragmatic, unblinded, multicenter, randomized con- trolled trial was conducted in three National Health Service stop-smoking sites across the U.K. Smokers (N=886) who were neither pregnant nor breastfeeding with no clear quit date were recruited and randomized to either nicotine replacement therapies of their choice and combination or an e-cigarette starter pack with instructions to purchase further e-liquids of their choice for up to 3 months. Weekly counseling was also provided to all participants and was continued for 4 weeks after the quit date. Abstinence was queried at 26 and 52 weeks with biochemical confirmation at the latter if >50% reduction was reported. The sustained abstinence rate at 1 year was 18% among the e-cigarette users and 9.9% among the NRT users with a relative risk of abstinence of 1.83 (CI=1.30 – 2.58, 95%, p<0.001). Both e-cigarettes and NRT were considered less satisfying than cigarettes but e-cigarettes provided greater satisfaction than NRT. While only 9% of the abstinent NRT users were still using NRT at 1 year, more than 80% of the abstinent e-cigarette users were continuing to use these products.

RkJQdWJsaXNoZXIy MTM1ODMw